Citation: | ZHANG Li-li, ZHANG Dong-mei, XIE Chang-hao. Clinical characteristics, treatment and follow-up analysis of newly diagnosed systemic lupus erythematosus associated thrombocytopenia[J]. Chinese Journal of General Practice, 2021, 19(5): 760-762,793. doi: 10.16766/j.cnki.issn.1674-4152.001910 |
[1] |
张雪, 孙娟, 谢长好, 等. 心理干预对育龄期系统性红斑狼疮患者的影响[J]. 中华全科医学, 2018, 16(10): 1762-1765. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201810049.htm
|
[2] |
钮凌颖, 周康兴, 王红. 系统性红斑狼疮患者合并感染临床特点及影响因素的分析[J]. 中国临床研究, 2016, 29(8): 1090-1092. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK201608023.htm
|
[3] |
JUNG J H, SOH M S, AHN Y H, et al. Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients[J]. Medicine, 2016, 95(6): 1-7. http://repository.ajou.ac.kr/bitstream/201003/15199/1/26871854.pdf
|
[4] |
MU L, HAO Y, FAN Y, et al. Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus[J]. Lupus, 2018, 7(10): 1742-1752. http://www.ncbi.nlm.nih.gov/pubmed/30060721
|
[5] |
CHEN Z, ZHONG H, DONG G. Thrombocytopenia as a prognostic marker for systemic lupus erythematosus: a systematic review and meta-analysis[J]. Am J Med Sci, 2019, 357(6): 461-467. doi: 10.1016/j.amjms.2019.03.002
|
[6] |
LIU Y, CHEN S, SUN Y, et al. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: a retrospective study[J]. Medicine(Baltimore), 2016, 95(50): 1-6. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5268034/pdf/md-95-e5565.pdf
|
[7] |
龙现明, 蔡成森, 周欣, 等. 系统性红斑狼疮继发难治性血小板减少的临床特征分析[J]. 中华风湿病学杂志, 2020, 24(3): 170-174. https://cdmd.cnki.com.cn/Article/CDMD-10023-1017225065.htm
|
[8] |
姜楠, 赵久良, 李梦涛, 等. CSTAR注册研究: 初治系统性红斑狼疮相关血小板减少症的临床特点[J]. 中华临床免疫和变态反应杂志, 2017, 11(2): 101-105. https://www.cnki.com.cn/Article/CJFDTOTAL-OZHL201702001.htm
|
[9] |
PAWLAK-BUS K, LESZCZYNSKI P, KOKOT M, et al. Thrombocytopenia resistent to standard therapy in lupus patients-analysis of 3 cases and clinical statement[J]. Ann Agric Environ Med, 2017, 25(2): 229-233. doi: 10.26444/aaem/80708
|
[10] |
MIRANDA-HERNANDEZ D, CRUZ-REYES C, MONSEBAIZ-MORA C, et al. Active haematological manifestations of systemic lupus erythematosus lupus are associated with a high rate of in-hospital mortality[J]. Lupus, 2017, 26(6): 640-645. doi: 10.1177/0961203316672926
|
[11] |
JIANG N, LI M, ZHANG M, et al. Chinese SLE Treatment and Research group(CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus[J]. PLoS One, 2019, 14(11): 1-16. http://www.ncbi.nlm.nih.gov/pubmed/31747435
|
[12] |
ARTIM-ESEN B, CENE E, SAHINKAYA Y, et al. Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival[J]. Lupus, 2019, 28(12): 1480-1487. doi: 10.1177/0961203319877245
|
[13] |
ABDEL GALIL S M, EDREES A M, AJEEB A K, et al. Prognostic significance of platelet count in SLE patients[J]. Platelets, 2017, 28(2): 203-207. doi: 10.1080/09537104.2016.1214253
|
[14] |
LINNEMANN B. Antiphospholipid syndrome-an update[J]. Vasa, 2018, 47(6): 451-464. doi: 10.1024/0301-1526/a000723
|
[15] |
KOH J H, PARK E K, LEE H N, et al. Clinical characteristics and survival of 413 patients with systemic lupus erythematosus in southeastern areas of South Korea: A multicenter retrospective cohort study[J]. Int J Rheum Dis, 2020, 23(1): 92-100. http://d.wanfangdata.com.cn/periodical/807ff6d2ea0294a7dfe75020b6e630a5
|
[16] |
TEKE H U, CANSU D U, KORKMAZ C. Detailed features of hematological involvement and medication-induced cytopenia in systemic lupus erythematosus patients: single center results of 221 patients[J]. Eur J Rheumatol, 2017, 4(2): 87-92. http://pubmedcentralcanada.ca/pmcc/articles/PMC5473461/
|
[17] |
GONZLEZ-NARANJO L A, BETANCUR O M, ALARCN G S, et al. Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort[J]. Semin Arthritis Rheum, 2016, 46(6): 675-683. http://www.ncbi.nlm.nih.gov/pubmed/26698222
|
[18] |
ZHAO L, XU D, QIAO L, et al. Bone marrow megakaryocytes may predict therapeutic response of severe thrombocytopenia in patients with Systemic Lupus Erythematosus[J]. J Rheu matol, 2016, 43(6): 1038-1044. http://www.ncbi.nlm.nih.gov/pubmed/27134253
|
[19] |
LI J, PAN Z, LIU H, et al. Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus[J]. Medicine(Baltimore), 2018, 97(27): 1-5. http://europepmc.org/abstract/MED/29979417
|
[20] |
MOK C C, HO L Y, TSE S M, et al. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus[J]. Ann Rheum Dis, 2017, 76(8): 1420-1425. http://europepmc.org/abstract/MED/28432050
|